Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC): can this lead to the adverse effect of hypogonadism?

Mehran Afshar, Hiten R. H. Patel, Ankit Jain, Abhishek Kumar, Prashant Patel, Nicholas James, Emilio Porfiri

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Fingerprint

Dive into the research topics of 'Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC): can this lead to the adverse effect of hypogonadism?'. Together they form a unique fingerprint.

Medicine & Life Sciences